the 503A question that gets asked weekly, answered properly
Posting this as a discussion rather than a claim: the 503A question that gets asked weekly, answered properly. Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label. A beyond-use date derived from published…
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
the pharmacy and the prescriber are two separate questions
What did the intake actually ask you?
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
the label on a compounded vial is a legal document, read it
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Compounded preparations are not approved products and carry no bioequivalence claim.
bruno_dumitru is right about the concentration trap. It breaks arithmetic that has been reliable for months.
What is the beyond-use date and what is it based on?
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.